Rhumbline Advisers Has $366,000 Stake in Korro Bio, Inc. (NASDAQ:KRRO)

Rhumbline Advisers boosted its position in shares of Korro Bio, Inc. (NASDAQ:KRRO) by 7.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 9,602 shares of the company’s stock after buying an additional 691 shares during the quarter. Rhumbline Advisers’ holdings in Korro Bio were worth $366,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its holdings in shares of Korro Bio by 374.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 12,391 shares of the company’s stock valued at $414,000 after purchasing an additional 9,782 shares during the period. Vestcor Inc bought a new stake in Korro Bio in the third quarter valued at approximately $100,000. Wellington Management Group LLP acquired a new stake in shares of Korro Bio in the third quarter valued at approximately $436,000. State Street Corp boosted its stake in shares of Korro Bio by 18.9% during the 3rd quarter. State Street Corp now owns 118,765 shares of the company’s stock worth $3,969,000 after acquiring an additional 18,877 shares during the period. Finally, MetLife Investment Management LLC boosted its stake in shares of Korro Bio by 129.0% during the 3rd quarter. MetLife Investment Management LLC now owns 3,639 shares of the company’s stock worth $122,000 after acquiring an additional 2,050 shares during the period. Institutional investors and hedge funds own 13.18% of the company’s stock.

Korro Bio Price Performance

KRRO opened at $22.33 on Monday. The stock has a fifty day moving average of $33.01 and a 200-day moving average of $43.04. Korro Bio, Inc. has a fifty-two week low of $20.34 and a fifty-two week high of $98.00.

Wall Street Analysts Forecast Growth

KRRO has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $115.00 price target on shares of Korro Bio in a report on Friday, November 22nd. Oppenheimer began coverage on shares of Korro Bio in a research report on Friday, January 10th. They issued an “outperform” rating and a $155.00 price objective on the stock. Finally, William Blair reaffirmed an “outperform” rating on shares of Korro Bio in a report on Wednesday, November 13th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $144.00.

Korro Bio Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).